These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19574209)

  • 1. Intertrigo-like eruption caused by pegylated liposomal doxorubicin (PLD).
    Sánchez Henarejos P; Ros Martínez S; Marín Zafra GR; Alonso Romero JL; Navarrete Montoya A
    Clin Transl Oncol; 2009 Jul; 11(7):486-7. PubMed ID: 19574209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An intertrigo-like eruption from pegylated liposomal doxorubicin.
    Korver GE; Ronald H; Petersen MJ
    J Drugs Dermatol; 2006 Oct; 5(9):901-2. PubMed ID: 17039658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case of severe bullous erythema including intertrigo-like eruptions with angioedema induced by pegylated liposomal doxorubicin.
    Totsuka M; Watanabe Y; Asai C; Takahashi S; Ishikawa H; Takamura N; Hagiwara M; Aihara M
    J Dermatol; 2019 Jun; 46(6):535-539. PubMed ID: 31021010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intertrigo-like dermatitis with pegylated liposomal doxorubicin: diagnosis and management.
    Najem A; Deregnaucourt D; Ramdane S; Dridba M; Djouba F; Vercambre-Darras S
    J Clin Oncol; 2014 Nov; 32(31):e104-6. PubMed ID: 24550424
    [No Abstract]   [Full Text] [Related]  

  • 5. Striking follicular eruption to pegylated liposomal doxorubicin.
    Dai J; Micheletti R; Rosenbach M; Chu EY
    Am J Dermatopathol; 2014 Jul; 36(7):590-1. PubMed ID: 24614205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucocutaneous toxicity induced by pegylated liposomal doxorubicin: a single-institution, retrospective case series.
    Vaccaro M; Santarpia M; Calapai G; Mannucci C; Borgia F; Altavilla G; Cannavò SP
    Br J Dermatol; 2017 Feb; 176(2):507-509. PubMed ID: 27291307
    [No Abstract]   [Full Text] [Related]  

  • 7. Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin.
    English JC; Toney R; Patterson JW
    J Cutan Pathol; 2003 Oct; 30(9):591-5. PubMed ID: 14507411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegylated liposomal doxorubicin as neoadjuvant therapy for stage II-III locally advanced breast cancer.
    Yao J; Pan S; Fan X; Jiang X; Yang Y; Jin J; Liu Y
    J Chemother; 2020 Jul; 32(4):202-207. PubMed ID: 32281493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.
    Martínková J; Bláha M; Kubeček O; Maláková J; Špaček J; Bezouška J; Krulichová IS; Filip S
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):429-37. PubMed ID: 26678853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience.
    Martin-Romano P; Baraibar I; Espinós J; Legaspi J; López-Picazo JM; Aramendía JM; Fernández OA; Santisteban M
    Breast J; 2018 Jul; 24(4):473-479. PubMed ID: 29286192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated Liposomal Doxorubicin as Adjuvant Therapy for Stage I-III Operable Breast Cancer.
    Lu YC; Ou-Yang FU; Hsieh CM; Chang KJ; Chen DR; Tu CW; Wang HC; Hou MF
    In Vivo; 2016; 30(2):159-63. PubMed ID: 26912829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Skin problems associated with pegylated liposomal doxorubicin -- more than palmoplantar erythrodysesthesia syndrome".
    Von Moos R; Cathomas R
    Eur J Dermatol; 2009; 19(3):264-5. PubMed ID: 19213658
    [No Abstract]   [Full Text] [Related]  

  • 13. What is the right way to administer pegylated liposomal doxorubicin in breast cancer therapy?
    Grenader T; Gabizon A
    J Clin Oncol; 2010 Apr; 28(12):e193-4; author reply e195-6. PubMed ID: 20194839
    [No Abstract]   [Full Text] [Related]  

  • 14. Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report.
    Munzone E; Di Pietro A; Goldhirsch A; Minchella I; Verri E; Cossu Rocca M; Marenghi C; Curigliano G; Radice D; Adamoli L; Nolè F
    Breast; 2010 Feb; 19(1):33-7. PubMed ID: 19884008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe palmoplantar erythrodysesthesia and intertrigolike eruption induced by polyethylene glycol-coated liposomal doxorubicin.
    Campanelli A; Kerl K; Lübbe J
    J Eur Acad Dermatol Venereol; 2006 Sep; 20(8):1022-4. PubMed ID: 16922969
    [No Abstract]   [Full Text] [Related]  

  • 16. Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review.
    Savani M; Woerner K; Bu L; Birkenbach M; Skubitz KM
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):289-294. PubMed ID: 33388949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
    Al-Batran SE; Meerpohl HG; von Minckwitz G; Atmaca A; Kleeberg U; Harbeck N; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
    Oncology; 2006; 70(2):141-6. PubMed ID: 16645327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial).
    Eckes J; Schmah O; Siebers JW; Groh U; Zschiedrich S; Rautenberg B; Hasenburg A; Jansen M; Hug MJ; Winkler K; Pütz G
    BMC Cancer; 2011 Aug; 11():337. PubMed ID: 21816044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
    Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
    Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrotic syndrome and acute renal failure during pegylated liposomal doxorubicin treatment.
    Carron PL; Padilla M; Maurizi Balzan J
    Hemodial Int; 2014 Oct; 18(4):846-7. PubMed ID: 25040096
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.